Instadose Pharma Corp.

As of February 28, 2022, Instadose Pharma Corp. carries a market capitalization of 3.19B, placing it among publicly traded companies globally. Its enterprise value stands at 3.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of February 28, 2022, Instadose Pharma Corp. has 531.93M shares outstanding.

These figures are as of February 28, 2022.

As of February 28, 2022, Instadose Pharma Corp. maintains a current ratio of 0.01, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended February 28, 2022. Return on assets (ROA) is negative at -7.50, reflecting losses generated across the asset base.

As of the close on October 5, 2026, Instadose Pharma Corp.'s stock has gained approximately 9900.00% over the past 52 weeks.

Over the twelve months ended February 28, 2022, Instadose Pharma Corp. generated - - in revenue and converted that into -1.72M in net income, yielding earnings per share of -0.01. EBITDA reached -1.21M, while operating income came in at -1.70M.

As of February 28, 2022, Instadose Pharma Corp. holds 5,328.00 in cash and equivalents against 237,524.00 in total debt, resulting in a net debt position of 46,503.00. Total book value stands at 35.66M, with working capital of -10.11M providing operational flexibility.

Instadose Pharma Corp. produced 696,259.18 in operating cash flow over the twelve months ended February 28, 2022. After subtracting - - in capital expenditures, free cash flow totaled 696,259.18 - equivalent to 0.00 per share.

These figures cover the twelve months ended February 28, 2022. Free cash flow yield stands at 0.06, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.03, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Instadose Pharma Corp. shareholders.

As of February 28, 2022, Instadose Pharma Corp. has an Altman Z-Score of 142.39, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.